Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Tuesday, September 15, 2026

⚡ Executive Takeaway

Forced disclosure week is one session old and already sorting sponsors into two piles. AstraZeneca spent the weekend printing everything it had: a Saturday miss with no spin, then a Seoul dataset whose interim survival number currently points the wrong way, published anyway, next to a fatal pneumonitis rate. The stock finished higher. Scholar Rock's regulator did the printing for it, delivering a forced date nineteen days before it came due. Amgen, holding the only major undisclosed dataset of the congress, watched three rival lung cancer sponsors put full survival tables on the board while its own four session slide stopped only when the calendar reached the eve of its forced appearance.

The pattern we set Monday is running ahead of schedule: the discount attaches to silence, not to bad news. A sponsor that prints an uncomfortable number is telling you it can afford to; one that keeps holding a good number is inviting you to ask why. Tomorrow at 11:30 am Eastern, Amgen takes questions in public with both of its language tests live. We grade them in Wednesday's edition. 👉 Read Full Analysis

🧬 Rare Disease

The FDA showed up nineteen days early, and the stock treated the approval like a bill. SRRK

The FDA approved Isembyld (apitegromab-mstn), the first muscle targeted treatment in spinal muscular atrophy, for patients two and older who are on SMN2 targeted therapy, in a release Scholar Rock issued Friday at 6:25 pm Eastern, 19 days before the September 30 action date by our arithmetic. The SAPPHIRE trial behind it randomized 188 patients and delivered a 2.2 point motor function improvement over SMN2 therapy alone (p=0.0121), with 34.2% versus 13.5% achieving a three point gain. The approval carries a rare pediatric disease priority review voucher, product ships within days, and the file that lost its European application over a fill finish facility switch just finished its American review ahead of schedule. What is missing is the price: none was disclosed, and shares fell 6.4% in Monday's first session after the news. Market data, no cause assigned, but the launch price is now the number that matters for a drug layered on top of therapies that already cost payers six figures a year.

🫁 Lung Cancer

AstraZeneca printed the number nobody prints. AZN

The DESTINY-Lung04 detail arrived at WCLC's Presidential Symposium: Enhertu delivered a median progression free survival of 14.3 versus 8.3 months, hazard ratio 0.63, with a 70.0% response rate against 44.5% for pembrolizumab plus chemotherapy, the first Phase 3 win over the global standard in first line HER2 mutant non small cell lung cancer. Then the companies printed the rest: interim overall survival, 46.9% mature, of 29.3 versus 33.1 months, hazard ratio 1.15, currently favoring the control arm, plus interstitial lung disease in 20.8% of Enhertu patients including 1.8% fatal cases. An immature interim with a confidence interval from 0.88 to 1.52 is not evidence of harm, and the trial runs to a final survival analysis. But they put it on the table. AZN closed up 2.3% Monday, the first session after both the Saturday SERENA-4 disclosure and this. The Pro brief takes the uncomfortable number seriously.

🎗️ Oncology

The second B7-H3 ADC posted the same hazard ratio as the first, to the decimal. RHHBY | GSK

Roche collaborator MediLink's tambotatug pelitecan (Tam-Peli) cut the risk of death 54% in relapsed small cell lung cancer in the 451 patient TAISHAN-302 trial, median overall survival 13.3 versus 9.4 months against topotecan, hazard ratio 0.46, published simultaneously in the New England Journal of Medicine. That hazard ratio, and even its confidence interval, matches Hansoh's ARTEMIS-008 result for risvutatug rezetecan exactly, though the medians differ: 18.5 months for the Hansoh drug, 13.3 here, both in China only trials. Roche holds rights everywhere outside mainland China, Hong Kong and Macau and says it will rapidly start global Phase 3 trials; GSK's global trial for the Hansoh drug reads out in 2027. Two independent trials, one hazard ratio: B7-H3 is a validated class, and the ex China rights sit with two of the largest oncology franchises in the world. The congress's other small cell headline, Amgen's DeLLphi-305, remained numberless as the meeting entered its final day.

🧠 CNS

Definium's LSD pill did it a third time. DFTX

The Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder beat placebo by 5.1 points on the Hamilton Anxiety Rating Scale at week 12, p<0.0001, replicating the Voyage study's 5.4 point result, with separation visible at week one and on day two. Response rate ran 32% versus 14%, remission 15% versus 4%, and safety again showed no suicidality signal, with transient illusion on dosing day the most common event at 68%. Definium plans a pre NDA meeting this quarter and an NDA filing in the first half of 2027 on what it calls four complementary positive studies. Shares rose 3.5%. The most advanced psychedelic derived program in psychiatry now has a replicated pivotal package, which turns the FDA's posture on this class from an academic question into a commercial one.

⚖️ Obesity

Corbus just made CB1 respectable again. The market wanted more than respectable. CRBP

Corbus's oral, peripherally restricted CB1 inverse agonist CRB-913 produced 5.0% weight loss at the top dose over 12 weeks versus zero for placebo in the 254 patient CANYON-1 study, with 44.4% of top dose patients losing at least 5%. The line that matters is neuropsychiatric: one transient moderate depressive event among 188 dosed, and no serious or severe psychiatric adverse events, in the mechanism that sank rimonabant and that Novo shelved monlunabant over. Efficacy is modest against incretins, which is why the company frames it as combination and maintenance therapy; the data go to ObesityWeek in November and Phase 2 starts in the first half of 2027. Shares churned nearly four times Friday's volume and closed down 0.5%. The same day, Eli Lilly discontinued an early obesity candidate that Fierce Biotech reports failed to clear an internal bar. A clean 5% at 12 weeks now buys a combination slot, not a franchise.

📉 The Tape

The reaction session rewarded the printers. AZN | SRRK | AMGN | AMLX

Official September 14 closes: AZN 163.78, up 2.3%, first session after the Saturday SERENA-4 disclosure, so the miss did not price; SRRK 51.85, down 6.4% in the first session after the Friday evening approval, list price still undisclosed; AMGN 381.50, up 1.1%, ending a four session slide the day before its Morgan Stanley appearance; AMLX 33.64, up 6.4%, an eleventh straight close below the $35.50 offer, with the offering's closing still unannounced in tonight's check and the greenshoe forcing paperwork by about September 18. Elsewhere: RARE 13.61, down 4.8%, with UX111 due Friday; DFTX 40.25, up 3.5%; CRBP 8.08, down 0.5%; CGEM 20.40, down 0.9%; BSX 45.05, up 4.8%; EXEL 56.21, up 0.2%, still with no company release on the March 3 date; BHVN 12.64, down 0.6%. No cause assigned to any move without a company disclosure.

📋 Quick Hits

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

The regulator everyone models as a delay machine just handed back nineteen days, and the sponsor everyone models as a winner is the only one still holding its number. Both of those prices move this week. What are you watching? Reply to this email.

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →